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Building upon the growing interest and research on genetically modified (GM) biofortification, its socioeconomic 
potential has been increasingly examined. We conducted two systematic reviews and meta-analyses to provide 
comprehensive evidence of consumers’ willingness to pay (11 economic valuation studies, 64 estimates) and cost-
effectiveness/benefits (five economic evaluation studies, 30 estimates). Worldwide, consumers were willing to pay 
23.9% more for GM biofortified food crops. Aside from crop and design-related differences, information provision 
was deemed crucial. Positive information (nutrition and GM benefits) is associated with the highest consumer 
willingness to pay, compared with negative, objective, and conflicting GM information, especially when negative 
information was mentioned last. This health intervention would reduce the aggregated micronutrient deficiency 
burden in Asia (15.6 million disability-adjusted life years (DALYs)) by 12.5–51.4%, at a low cost of USD 7.9–27.8 
per DALY in a pessimistic and optimistic scenario, respectively. Given that GM biofortified crops could tackle 
hidden hunger in a cost-effective and well-accepted way, its implementation is worth pursuing. A case study on folate 
biofortification further elaborates on the importance of socioeconomic research and the determinants of their market 
potential.
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Introduction
Micronutrient malnutrition is still widespread in
children and women from poor, developing regions.
Currently, one out of three people in the world suf-
fers from a chronic deficiency of one or, more often,
multiple essential vitamins and minerals.1,2 While
this global affliction is often referred to as hidden
hunger, due to an inferior quality of food consump-
tion rather than a lack of food as such, its conse-
quences are far from hidden. With a share of 7% of
the annual global burden of disease,3 micronutrient
malnutrition is known to have far-reaching adverse
consequences for both public health and economic
development.
a Both authors contributed equally to this work and are
co-first authors.
Of the large array of nutrition-sensitive inter-
ventions, agriculture–nutrition linkages are worth
considering,4,5 given that various plant-based foods
provide most of the nutrients required for good
health. Malnourished populations usually lack
access to such micronutrient-rich foods, as they rely
on few, less-expensive major staple crops, which are
characterized by low micronutrient concentrations.
As a consequence, agriculture is increasingly advo-
cated as a means not only to reduce hunger through
enhancing productivity but also to tackle hidden
hunger through improving food quality.
Against this background, biofortification has
been introduced as a sustainable, prorural, pro-
poor strategy to improve micronutrient intake
levels in target populations6–8 and a valuable com-
plement to supplementation and fortification.9,10
Biofortification refers to all strategies that enhance
the nutritional quality of food crops, either through
traditional plant breeding (conventional bioforti-
fication), fertilizer application (agronomic biofor-
tification), or intragenic/transgenic plant breeding
(genetically modified (GM) biofortification). Since
2003, substantial progress has been made by the
HarvestPlus program through testing or releasing
various conventional biofortified crops in more
than 50 priority countries.11,12 While there is still 
unexplored potential,13,14 this program already 
successfully targets vitamin A, iron, or zinc levels in
seven key crops (cassava, corn, sweet potato, bean,
pearl millet, rice, and wheat) and aims to introduce
additional varieties in the near future.
Notwithstanding the growing evidence on the
successes of conventional biofortification, as stud-
ies on breeding efforts and efficacy and effective-
ness trials have shown,8,10,15 biotechnology-based 
approaches are sometimes needed (e.g., when the
nutrient is not naturally present in the target
crop (e.g., vitamin A–enriched golden rice)16 or 
is present only in marginal amounts, or when
conventional methods are insufficient to obtain
substantial enhancement (e.g., folate biofortifica-
tion of rice17,18)). Furthermore, they can increase 
micronutrient levels in the desired tissue, such as
cereal endosperm, to avoid postmilling micronutri-
ent losses through the outer layers.
Despite the various promising efforts in research
and development for the use of biotechnology for
developing micronutrient-rich crops8,19,20 (e.g., 
effectiveness of golden rice21 and the stability of 
folate-biofortified rice22), it is plagued by contro-
versy while facing various political and regulatory
hurdles,23,24 which also impedes commercialization 
of the first GM biofortified crop. Aside from these
forces, the success of their future commercialization
will also hinge on its societal impacts. As a policy
intervention, such consumer-oriented (second-
generation) GM crops are expected to generate
substantial health effects at a relatively low cost, in
line with the high cost-effectiveness of conventional
biofortified crops.25
Moreover, it will also be key to introduce such bio-
engineered biofortified crops under the right market
conditions. To effectively support regions where the
need to enhance micronutrient intake levels through
such GM crops is highest, consumers should first
embrace these crops. Besides technical prerequisites,
particularly the bioavailability and stability of the
targeted vitamins or minerals, it is the consumer
who will ultimately determine the magnitude of the
reduction of micronutrient malnutrition through
GM biofortified crops. When looking at consumer
studies on conventional biofortified crops,26 posi-
tive reactions were generally reported by target pop-
ulations, in terms of both sensory acceptance and
willingness to pay (WTP). Whether or not nutrition
traits are visible (e.g., vitamin A–enriched yellow
corn), sensory attributes of conventional bioforti-
fied crops are often equally or—especially in case
health information is provided—better evaluated
than their regular counterparts. These positive find-
ings are reflected in consumers’ purchase behavior,
as they were prepared to pay premiums between 6%
and 50%.
Similar to conventional biofortified food
research, socioeconomic studies on GM bioforti-
fied crops is growing to demonstrate proof of con-
cept. Consequently, this paper presents a systematic
review and meta-analysis on the socioeconomics
of such GM crops with higher micronutrient lev-
els. Therefore, the focus will be on (1) consumers’
WTP (economic valuation) and (2) potential cost-
effectiveness/cost–benefits (economic evaluation).
Given that several studies are targeted toward (cur-
rently) hypothetical GM biofortified staple crops,
this meta-analysis will estimate potential cross-
product demands and ex-ante health effect sizes. In
addition, (3) folate-biofortified rice will be reviewed
as a case to provide an in-depth analysis of socioe-
conomic evidence, mainly focusing on the deter-
minants of acceptance, WTP, health impact, and
cost-effectiveness. A compilation of such evidence
could lead to a better understanding of the potential
value of GM biofortification, hence providing the
scientific rationale for its future commercialization.
Methods
This systematic review and meta-analysis has to
be situated in the field of agricultural economics.
Therefore, we followed the guidelines of the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses statement27 that are applicable and
relevant to this field, as well as the procedures in
reviews on GM food valuations.28,29
Eligibility criteria
By searching the Institute for Scientific Infor-
mation Web of Science and AgEcon databases,
peer-reviewed socioeconomic studies that inves-
tigated (1)  WTP as a measure of consumer  
preference (economic-valuation studies) and (2)
cost-effectiveness or cost–benefits of GM biofor-
tified crops (economic-evaluation studies) were
eligible for systematic review and meta-analysis.
Additional and more specific inclusion and
exclusion criteria were used to narrow the search
down to the relevant studies. To be included in both
the systematic review and meta-analysis for WTP,
a study had to be written in English or French,
target a specific micronutrient and GM crop, and
report a WTP estimate (i.e., percentage premium
or mean from which the former could be derived).
A study was excluded if it determined consumer
preference without economic-valuation methods
(e.g., through sensory evaluation (nonexistent for
nonapproved GM biofortified crops) or hedonic
testing techniques30,31), or if it expressed WTP only 
as a percentage of a sample intended to purchase
GM biofortified crops.32,33 For cost-effectiveness 
and cost–benefits, only English or French studies
analyzing a specific GM crop with a higher level of
one or more specific micronutrients were retained.
Thereby, a study must have reported an outcome
measure based on the disability-adjusted life
year (DALY) approach (e.g., cost to gain a DALY
through the introduction of GM biofortified crops
(cost-effectiveness), a benefit–cost ratio (BCR), or
an internal rate of return (IRR) (cost–benefits)).
As a consequence, burden and health-impact
indicators (i.e., DALYs lost/gained and percent
reduction in disease burden) could also be
obtained. The DALY method is the standard mea-
surement tool of the World Health Organization
(WHO) for global burden of disease assessment
and evaluation of the contribution of health
interventions in alleviating disease burden.34,35
More recently, it has been applied to measure the
cost-effectiveness of conventional25 or GE36 bio-
fortified crops (for a methodological description,
see Ref. 37).
Four outcome variables were eligible for meta-
analysis on both topics: percent WTP versus
cost per DALY saved and percent IRR or BCR.
The rationale behind this selection was the need
for a common data parameter across, respec-
tively, WTP and cost-effectiveness/cost–benefit
studies that is easily amendable to an appropriate
meta-analysis.
Study search and selection
The search for articles was carried out in October
2015 and later updated on November 21, 2015. The
search syntax was developed using Web of Knowl-
edge and consists of a combination of the fol-
lowing keywords: (biofortification or similar; GM
(crop/food) or similar; golden rice) AND (accep-
tance, purchase intention, preferences, valuation,
WTP, or similar) for WTP studies on one hand,
AND (health impact or similar; cost-effectiveness,
cost–benefit or similar) for cost-effectiveness/cost–
benefit studies on the other. This broad syntax with
regard to biofortified crops was used because socioe-
conomic studies are not only limited to the use of
universal terminology (for a discussion, see WHO
efforts on defining biofortification38) but also refer
to specific terms like “golden rice.” This reduced the
likelihood that relevant studies were omitted at an
early stage. All papers ready for scrutiny were trans-
ferred to Endnote (version X7, Thomson Reuters),
and doubles were removed. Two researchers con-
ducted the search. The first step was based on title
search for existence of keywords that were impor-
tant to the research question at hand. An abstract
screening followed to gauge additional relevance of
studies, and finally those deemed important were
subjected to an in-depth critical full article review.
At every search step, a cross-check was made by each
researcher, who reviewed 30% of both included and
excluded articles of the other researcher as a way to
ensure that a potentially relevant or irrelevant study
is not omitted or selected, respectively. In case a con-
sensus could not be reached, an external opinion was
sought.
Data extraction
To have a comprehensive understanding of the
characteristics of the studies, data extraction sheets
were developed to facilitate coding of information
(Tables 1 and 2). Information extracted from
economic-valuation studies included crop,
micronutrient, breeding technique, United Nations
(UN) subregion, country of study, year of data
collection, setting, subjects, sample size, method
of data collection, nature of study, and the main
findings (split up according to information treat-
ment). On the basis of what was observed is the
systematic review and for the purpose of per-
forming a meta-analysis, the percentage premium
was extracted from the preference studies as a
Table 1. Systematic review of willingness-to-pay studies on GM biofortified crops: overview of key study character-









collection Nature of study
Main findings
(% premium)a Reference
Rice Vitamin A Transgenic North
America
USA 2001 Urban Adults 574 Mail survey
(CV)
Hypothetical 19.5% (PNU) 40
2004 Urban Adults 501 Mail survey
(CV)
Hypothetical 38.0% (PNU) 41
Southern Asia India 2006 Urban Adults 712 Mixed-method
studyb
Hypothetical 19.5% (CNP) 42
2009 Urban Students 154 In-person
survey (CV)
Hypothetical 3.8% (No) 43
Southeastern
Asia
Philippines 2006 Urban Students 60 Experiment
(choice exp.)









































Cassava Vitamin A Transgenic South
America
Brazil 2006 Rural Adults 414 In-person
survey (CV)




Potato Vitamin C Intragenic North
America
USA 2007 Urban Adults 98 Experiment
(auction)








USA 2007 Urban Adults 98 Experiment
(auction)






Broccoli Vitamin C Intragenic North
America
USA 2007 Urban Adults 98 Experiment
(auction)








USA 2007 Urban Adults 98 Experiment
(auction)






Tomato Vitamin C Intragenic North
America
USA 2007 Urban Adults 98 Experiment
(auction)








USA 2007 Urban Adults 98 Experiment
(auction)
















collection Nature of study
Main findings
(% premium)a Reference
Apple Vitamin C Transgenic Australia and
New
Zealand
New Zealand 2005 Urban Adults 146 Experiment
(auction)
Non-hypothetical 48.0% (No) 50
CR, contingent ranking; CV, contingent valuation; No, no information; PNU, positive information (nutrition benefits); PGM, positive
information (GM benefits); NGM, negative information (GM risks); OGM, objective; CPN, conflicting information (PGM + NGM);
CNP, conflicting information (NGM +PGM); CPNO, conflicting information (PGM+NGM+ OGM).
aPercent premium for GM biofortified food over the conventional counterpart. Average premiums are presented, unless information
was given (information treatment code between brackets). Negative values refer to a discount. Positive information was mainly
derived from statements of probiotech organizations/companies, while negative information was commonly based on antibiotech
statements. For a representative example, see Ref. 49.
bIn-person (n = 602) and online survey (n = 110); WTP elicited through random utility method.
cWomen of childbearing age.
dSome of the values were derived from raw data of the study or other publications related to the same study.51,52
dependent variable. Together with the variables
from the systematic review, these data constitute
the metadata. In studies where a premium was not
explicitly reported but rather means were stated,
the following formula was used:
WTP (% premium)
= x̄ (WTPbiofortified) − x̄ (WTPnon−biofortified)
x̄ (WTPnon−biofortified)
×100.
If the premium for the nonbiofortified crop was
not available, researchers used the market price. In
case regression models were used, percentage pre-
miums were derived from the coefficients. Only a
few studies reported point estimates and confidence
intervals, which are important for a meta-analysis.
As a consequence, it was necessary to use sam-
ple sizes that were universally reported as a mea-
sure of precision (weighting variable) to cater for
variability that potentially exists in WTP estimates.
This has also been expressed in another GM food
review.28 Multiple estimates included from single
studies were nonoverlapping because their measure-
ment was based on a categorization of methodolog-
ical or contextual variables (e.g., information treat-
ments, crop, nutrient, and data collection method).
With respect to cost-effectiveness and cost–
benefits, the information sheet sought to obtain
crop, micronutrient, UN subregion, country,
burden, impact scenario, health impacts, cost-
effectiveness, and cost–benefits. All cost-effec-
tiveness indicators were expressed in USD per DALY
gained. Cost–benefits were presented through BCRs
or IRRs.
All socioeconomic findings related to the case
study of folate-biofortified rice were derived from
experts involved in the research consortium exam-
ining this crop.
Data analysis
First, in order to synthesize the data from the stud-
ies, two broad narrative overviews were made to
describe characteristics of the studies used in the
systematic reviews.
Second, for the meta-analysis on economic-
valuation studies, mean WTP values (percentage
premiums) and standard deviations were computed
from the data, grouped by key study character-
istics obtained from the systematic review. Com-
parisons within each characteristic were performed
using analysis of variance tests for possible statisti-
cal differences. In addition, an overall metamean
WTP summary was calculated using a random-
effects (RE) model weighted by the sample size of
each study. This controls for possible heteroscedas-
ticity, due to the fact that—unlike the fixed-effects
(FE) model—studies differed in a number of ways
in which they were conducted (heterogeneity).39 A
specific analysis was run to illustrate the effect of
information treatments on WTP.
Third, regarding the meta-analyses on cost-
effectiveness and cost–benefits, average estimates
based on study characteristics were computed in
addition to simple overall means per economic-
evaluation indicator (reported by at least two
studies).
Results and discussion
Figure 1 depicts the process of the search strat-
egy on economic valuation and evaluation. The
Table 2. Systematic review of cost-effectiveness and cost–benefit studies on GM biofortified crops: overview of key
study characteristics and outcome indicators
Burden




















saved IRRa (%) BCR Reference
Mustard oilb Vitamin A Southern Asia India 20 Low 0.91 CEA/CBA 450.0a 22 57
High 1.69 CEA/CBA 403.0a 43 57
Rice Folate Eastern Asia China 30 0.31 Low 20 0.06 CEA 64.2 58
High 60 0.19 CEA 21.4 58
China, Shanxi 30 0.11 Low 20 0.02 CEA 120.3 59
High 60 0.07 CEA 40.1 59
Vitamin A Eastern Asia China 30 1.99 Low 17 0.33 CEA 18.1 58
High 60 1.20 CEA 5.0 58
Southern Asia India 30 2.33 Low 8.8 0.20 CEA/CBA 19.4 29 26 60
35 52
44 129





Philippines 16 0.27 Low 5.7 0.02 CBA 66 56
High 31.5 0.08 CBA 133 56
Multi- Eastern Asia China 30 10.64 Low 11 1.19 CEA 9.6 58
micronutrient High 46 4.91 CEA 2.3 58
Note: All studies are hypothetical in nature (ex-ante economic evaluation studies), all biofortified crops are developed through
transgenic breeding techniques or, in case of multivitamin-biofortified rice, through transgenic (vitamin A, folate) and conventional
(zinc, iron) breeding techniques.
BCR, benefit–cost ratio; CBA, cost–benefit analysis; CEA, cost-effectiveness analysis; DALY, disability-adjusted life year; IRR, internal
rate of return
aIRR represents the percentage yield per dollar spent per year. Therefore, each DALY saved is given a monetary value, either
standardized (USD 500, USD 1000, or USD 2500 in India) or a national per capita income (USD 1030 in the Philippines).
bDerived from GM biofortified mustard seed.61
two searches resulted in an initial total of 7058
records, of which 3560 and 3498 studies refer
to, respectively, economic-valuation and economic-
evaluation search terms. After screening and full-
text assessment, 11 and 5 articles, respectively, were
included in the synthesis. We obtained 64 WTP
estimates out of 11 consumer studies, each with a
corresponding sample size, and we derived 30 esti-
mates from the economic-evaluation studies. For
each topic, key characteristics of each individual
study will be summarized (Tables 1 and 2) before
discussing the findings from the meta-analysis
(Tables 3 and 4).
Willingness to pay for GM biofortified crops
Systematic review. The main characteristics of the
selected studies on WTP for GM biofortified crops
are summarized in Table 1 (64 estimates). Since
2001, when Lusk et al.40 elicited consumer prefer-
ences for golden rice in the United States, 11 studies
have reported WTP values for various GM bioforti-
fied crops.
Six food crops, of which three staple (rice,40–47
cassava,48 and potato49) and three nonstaple
crops (broccoli,49 tomato,49 and apple50) were
targeted. Except for the study of Colson et al.,49
who also examined the use of intragenic breeding
approaches (i.e., transferring genes from closely
related species capable of sexual hybridization53),
all studies looked at transgenic crops with a higher
vitamin content, either vitamin A,40–46 folate,46,47
or vitamin C.49,50 While, for nearly all products,
there were estimates elicited in urban, developed
settings, particularly in the United States, rice and
cassava were also selected for examining reactions
of consumers from developing countries, like
India and the Philippines (golden rice),40–45 China
(folate-biofortified rice),46,47 or Brazil (vitamin
A–enriched cassava).48 Except for a few studies
using students as the target group, most of the
WTP estimates refer to adults. Depending on the
data-collection method and the nature of the study,
the sample size ranged from 60 to 146 respondents
for non-hypothetical experiments and from 154
to 944 respondents for hypothetical survey meth-
ods. While the former build upon experimental
elicitation methods, such as choice experiments
or experimental auctions (uniform, second, or
Figure 1. Flow diagram of study search, selection, and review.
random nth price), the latter employed contingent
valuation/ranking techniques or random
utility methods. Below, the key findings will
be discussed for each crop, with particular attention
to information effects (see Fig. 2).
Rice (vitamin A, folate). From the reviewed
studies, two types of bioengineered rice were inves-
tigated, differentiated by the type of micronutri-
ent. First, golden rice, currently the most advanced
GM biofortified crop, was the subject of six
studies.40–43,45 Of these, two studies were carried
out with urban consumers from North America.40,41
Besides differences in year of data collection and
sample size, the first study also incorporated a cheap
talk script as a means to improve the validity of
non-hypothetical survey estimates.54 This might
contribute to the variation in WTP between the
studies (19.5–38.0%). The remaining four golden
rice studies were all conducted in Asia: two in
India42,43 and two in the Philippines.44,45 The design
of the Indian studies was relatively similar, except
for sample size and type of hypothetical valuation
method. Depending on the targeted study, Indian
consumers reported a low (3.8%)43 to—when
conflicting information about GM technology
is shown—high (19.5%)42 premium for this
yellowish vitamin A–enriched rice variety. In the
Philippines, two studies used a similar auction pro-
cedure, resulting in high premium levels of 40.0%45
or 66.7%,44 while one also conducted a choice exper-
iment (33.3%).44 When respondents were given spe-
cific positive information on GM technology, WTP
values increased in all studies, from 53.3% up to a
level of 120.0%. Much lower and even negative lev-
els are reported for negative GM information, either
alone (–13.3% to 6.7%) or after positive informa-
tion (–26.7% to 20.0%). Second, the two studies on
folate-biofortified rice examined consumers’ WTP
in Shanxi Province, a Chinese high-risk region for
folate deficiency.46,47 The 2008 survey46 with 944
consumers reported an average price premium of
34.0%, while a more recent auction47 with 251
subjects in 2011 revealed a similar premium in a
non-hypothetical setting (33.2%), although valua-
tions of the student sample (25.8%) were signif-
icantly lower than in the population-based sam-
ple (40.0%). The latter study also examined the
role of GM information, using treatments based on
positive, negative, or objective information or a
combination. Adults exhibited a higher WTP for
















Crop P = 0.246 Subjects P = 0.937
Rice 3647 31 (48.4) 24.7 (27.72) 40–47 Students 784 21 (32.8) 23.4 (33.03) 43–45, 47
Golden (vit.
A)
2201 16 (51.6) 26.3 (37.31) 40–45 Adults 4425 43 (67.2) 22.8 (28.18) 40–42, 46–50
Folate 1446 15 (48.4) 23.0 (12.20) 46, 47
Cassava (vit. A) 828 2 (3.2) 67.0 (4.24) 48 Nature of study P = 0.236
Potato (vit. C) 196 10 (16.1) 14.7 (32.15) 49 Hypothetical 3713 7 (10.9) 35.5 (24.25) 40–43, 46, 48
Broccoli (vit. C) 196 10 (16.1) 22.1 (31.59) 49 Non-hypothetical 1496 57 (89.1) 21.4 (30.00) 44, 45, 47, 49, 50
Tomato (vit. C) 196 10 (16.1) 15.4 (29.75) 49 Method of data
collection
P = 0.568
Apple (vit. C) 146 1 (1.6) 48.0 (0.00) 50 Experiment 1496 57 (89.1) 21.4 (30.00) 44, 45, 47, 49, 50
Micronutrient P = 0.372 In-person survey 1926 4 (6.2) 42.9 (30.48) 42, 43, 46, 48
Vitamin A 3029 18 (28.1) 30.8 (37.45) 40–45, 48 Mail survey 1075 2 (3.1) 28.8 (13.08) 40, 41
Folate 1446 15 (23.4) 23.0 (12.20) 46, 47 Mixed methodsa 712 1 (1.6) 19.5 (0.00) 42
Vitamin C 734 31 (48.4) 18.4 (30.27) 49, 50
Breeding technique P = 0.513 Type of information P = 0.000
Intragenic 294 15 (23.4) 27.4 (32.30) 49 Positive 2484 16 (25.0) 46.8 (28.86) 40, 41, 44, 45, 47, 49
Transgenic 4915 49 (76.6) 21.6 (28.9) 40–50 Nutrition (PNU) 2270 5 (31.2) 31.5 (8.62) 40, 41, 46, 47
GM (PGM) 214 11 (68.8 53.7 (32.40) 44, 45, 47, 49
Country P = 0.246 Negative GM (NGM) 215 11 (17.2) −7.0 (11.76) 44, 45, 47, 49
Philippines 260 12 (18.8) 28.3 (42.75) 44, 45 Objective GM (OGM) 42 2 (3.1) 24.5 (16.33) 47
China 1446 15 (23.4) 23.0 (12.20) 46, 47 Conflicting GM 1155 22 (34.4) 7.7 (17.19) 42, 44, 45, 47, 49
India 866 2 (3.1) 11.7 (11.10) 42, 43 Positive +
negative (CPN)
227 11 (50.0) 8.2 (20.12) 44, 45, 47, 49
USA 1663 32 (50.0) 18.1 (29.51) 40, 41, 49 Negative +
positive (CNP)
754 3 (13.6) 18.0 (3.54) 42, 47
Brazil 828 2 (3.1) 67.0 (4.24) 48 Positive +
negative +
objective (CPNO)
174 8 (36.4) 3.0 (15.26) 47, 49
New Zealand 146 1 (1.6) 48.0 (0.00) 50 None 1313 13 (20.3) 44.7 (19.52) 43, 48, 50
Setting P = 0.099
Rural 828 2 (3.1) 67.0 (4.24) 48
Urban 2223 46 (71.9) 21.1 (33.01) 40, 41,
43–45, 49,
50
Rural and urban 2158 16 (25.0) 22.8 (11.82) 42, 46, 47
Overall RE mean WTP % premium: 23.90 (SE 3.28)(CI 17.5–30.3)
Overall FE mean WTP % premium: 32.68 (SE 1.00)(CI 30.7–34.6)
Vit, vitamin; CI, confidence interval; PNU, positive information (nutrition benefits); PGM, positive information (GM benefits); NGM,
negative information (GM risks); OGM, objective; CPN, conflicting information (PGM+NGM); CNP, conflicting information (NGM
+PGM); CPNO, conflicting information (PGM+NGM+ OGM); SD, standard deviation; SE, standard error; RE, random effect; FE, fixed
effect.
aIn-person (n = 602) and online survey (n = 110).
folate rice than students when providing positive
information (36.5% vs. 21.5%), negative infor-
mation (12.7% vs. 7.3%), objective information
(36.0% vs. 12.9%), positive information followed by
negative information (43.1% vs. 7.9%), and a com-
bination of the three types (21.3% vs. 11.3%), but
not when the negative treatment preceded the pos-
itive one (14.0% vs. 20.6%).
Cassava (vitamin A). In rural Brazil, Gonzalez
et al.48 administered a survey with 414 consumers
to reveal their preferences for transgenic vitamin A–
enriched cassava. Using two hypothetical valuation
methods, Brazilian consumers were found to be pre-
pared to pay 64.0% or 70.0% more for transgenic
biofortified cassava.
Potato (vitamin C). An experimental auction
study in North America focused on vitamin
C–enriched potatoes—among two nonstaple
crops—developed either through intragenic or
transgenic breeding approaches.49 In the no-
information treatment, premiums for both potatoes
are similar, 60.8% and 62.3%, respectively. How-
ever, when specific GM-related information is given,
the intragenic biofortified potato elicits a substan-
tial higher value than when a transgenic trait would
be inserted: 49.8% versus 13.7% (positive), −12.3%
versus −21.9% (negative), 12.8% versus 0.0% (pos-
itive + negative), 2.2% versus −20.4% (positive +
negative + objective).
Nonstaple crops (broccoli, tomato, and apple). The
study of Colson et al.49 on intragenic and transgenic
potatoes enriched with vitamin C was also used to
determine WTP for two nonstaples, broccoli and
tomato. Regardless of the breeding approach, con-
sumers were willing to pay a premium for both prod-
ucts, when no information (32.6% and 34.8% for
Table 4. Meta-analysis on cost-effectiveness and cost–benefits of GM biofortified crops, including current burden of
disease and health impacts
Health impacts mean (SD) Cost-effectiveness mean (SD) Cost–benefit mean (SD)





lost per year Low High Low High Low High Low High Reference
Crop




22.00 (0.00) 43.00 (0.00) 57
Rice 3.11 (4.32) 0.36 (0.48) 1.15 (1.97) 12.50 (5.89) 51.38 (12.62) 27.83 (24.64) 7.95 (9.04) 47.50 (26.16) 99.50 (47.38) 56, 58–60
Micronutrient
Vitamin A 1.53 (1.10) 0.37 (0.39) 1.09 (0.70) 10.50 (5.84) 50.30 (16.28) 18.75 (0.92)b 4.05 (1.34)b 39.00 (23.64) 80.67 (46.76) 56, 58, 60
Folate 0.31 (0.00) 0.06 (0.00) 0.19 (0.00) 20.00 (0.00) 60.00 (0.00) 64.00 (0.00) 21.40 (0.00) 58, 59
Multi-micronutrient 10.64 (0.00) 1.19 (0.00) 4.91 (0.00) 11.00 (0.00) 46.00 (0.00) 9.60 (0.00) 2.30 (0.00) 58
Country
India 2.33 (0.00) 0.56 (0.50) 1.54 (0.22) 8.80 (0.00) 59.40 (0.00) 19.40 (0.00)b 3.10 (0.00)b 25.50 (4.95) 54.50 (16.26) 57, 60
China 4.31 (5.54) 0.53(0.59) 2.10 (2.49) 16.00 (4.58) 55.33 (8.08) 30.63 (29.38) 9.57 (10.34) 58, 59
Shanxi 0.11 (0.00) 0.02 (0.00) 0.07 (0.00) 20.00 (0.00) 60 (0.00) 120.3 (0.00) 40.1 (0.00) 59
Philippines 0.27 (0.00) 0.02 (0.00) 0.08 (0.00) 5.70 (0.00) 31.50 (0.00) – – 66.00 (0.00) 133.00 (0.00) 56
Overall mean 3.11 (1.93) 0.45 (SE 0.20) 1.58 (SE 0.72) 12.50 (SE 2.63) 51.38 (SE 5.64) 27.83 (SE 12.32)b 7.95 (SE 4.52)b 39.20 (SE 7.61) 82.40 (SE 15.04)
Note: If SD = 0, the metaresults are derived from single study findings. BCRs were only reported in Stein et al.60 (see Table 3) and
therefore not included in this meta-analysis.
DALY, disability-adjusted life year; ICER, incremental cost-effectiveness ratio; IRR, internal rate of return.
aDerived from GM biofortified mustard seed.61
bICERs of vitamin A–enriched mustard oil in India were only included at crop level (for mustard oil), as other cost-effectiveness
figures are based on data expressed in USD per DALY saved.
broccoli; 24.5% and 40.3% for tomato) or positive
GM information (37.7% and 93.9% for broccoli;
37.7% and 77.2% for tomato) was given. While
negative GM information led to a negative pre-
mium (discount) in all four cases, ranging from
−11.3% to −21.0%, WTP values under the con-
flicting GM information (positive + negative) treat-
ment were less positive for the transgenic traits
(12.4% and 3.4% vs. 26.9% and 17.6% for intragenic
traits), especially when objective GM information
was included (−5.8% and −14.6% for transgenic
traits vs. 12.6% and 17.1% for intragenic traits).
In New Zealand, Kassardjian et al.50 discovered a
relatively high premium (48.0%) for apples biofor-
tified with vitamin C. As of today, this is the only
economic valuation study on consumers’ WTP for
biofortified fruits.
Meta-analysis. Table 3 combines the WTP
estimates based on study characteristics from
the systematic review into a meta-analysis across
all applicable studies. The overall (sample size)
weighted mean premium for GM biofortified crops
from the RE model is 23.9%, which is approxi-
mately 1.4-fold smaller than that from the FE model
(32.68%), but a more realistic estimate justified by
a significant heterogeneity test (P = 0.000; under
the null hypothesis that all studies share a com-
mon effect size). In other words, consumers have
exhibited positive preferences toward GM biofor-
tified crops and are prepared to pay 24% more as
compared with conventional crops. Below, mean
WTP values are discussed with reference to product
characteristics (crop, micronutrient, and technol-
ogy), study characteristics (country, setting, sub-
jects), methodology (nature of the study, method of
data collection), and provided information.
Crop. For the type of crop valued, rice alone
had nearly half the estimates (29 of 64). Across
eight studies, consumers were prepared to pay an
average premium of 24.1% for GM biofortified
rice, with golden rice (26.3%) being valued slightly
more highly than folate-biofortified rice (21.5%).
Although consumer preferences for GM biofor-
tified potato, broccoli, and tomato were derived
from one study, with 10 estimates for each product,
the average premiums differed (i.e., 14.7%, 22.1%,
and 15.4%, respectively.) Furthermore, cassava and
apple contributed the least number of estimates but
obtained the highest value (premiums of 67.0% and
48.0%, respectively).
Micronutrient. Of the three micronutrients
examined, seven studies on GM crops biofortified
with vitamin A generated the highest mean WTP
(30.5%, 18 estimates), followed by folate (21.5%,
13 estimates) and vitamin C (18.4%, 31 estimates),
both from two studies each.
Technology. Although only one study also exam-
ined valuations of intragenic foods49 (see Table 1 for
a comparison at product level), the metaresults show
Figure 2. Willingness to pay for GM biofortified crops classified by information treatments, per country, micronutrient, and crop.
Note: Bars with a dashed border refer to average mean values (percent premium) across studies, per information treatment. All
other bars are based on single-study estimates (see Table 1).
that consumers were on average willing to pay a pre-
mium of 27.4% for intragenic biofortified broccoli,
tomato, and potato together (15 estimates), which is
6.3% higher than the transgenic premium (21.1%,
47 estimates from 11 studies). As such, these results
confirm the discrepancy of WTP values according
to breeding technology.
Country. With 32 estimates from three stud-
ies, the United States is represented the most.
Unexpectedly, the premiums for GM biofortified
foods between people from developing or developed
regions are not significantly different. Consumers
in Brazil valued them the highest (67.0%), followed
by those in New Zealand (48.0%), the Philippines
(28.3%), China (21.5%), the United States (18.1%),
and India (11.1%).
Setting. On the basis of 46 estimates from seven
studies, the average premium of urban consumers
was estimated at 21.1%, which resembles the 21.3%
premium in both rural and urban settings (14 esti-
mates from three studies). However, the average pre-
mium emanating from one study targeting rural
consumers reached 67.0% (two estimates).
Subjects. Eight studies used adults in their sam-
ple of participants, resulting in 43 WTP estimates
compared with 19 estimates derived from six stud-
ies for which only students were recruited. However,
premium levels from both types of subjects did not
differ (i.e., 22.4% and 22.8% for students and adults,
respectively).
Nature of the study. Though insignificant, there
is a difference in mean WTP between the five hypo-
thetical and six non-hypothetical valuation studies:
35.5% (55 estimates) versus 21.0% (7 estimates).
Given the lack of monetary incentives in the hypo-
thetical setting, its lower premium is not a surprise
and confirms findings in the economic-valuation
literature (hypothetical bias).55
Method of data collection. Together, the experi-
mental studies resulted in a mean premium of 21%
(55 estimates). A low number of estimates were pro-
duced in the few studies that used survey techniques,
like in-person survey (42.9%, four estimates), mail
survey (28.8%, two estimates), or a combination of
online and in-person surveys (19.5%, one estimate),
which confirms the above-mentioned finding.
Information. The average premium a consumer
is prepared to pay for GM biofortified crops is sig-
nificantly different depending on the information
that he or she receives. Besides nutrition-related
information, all treatments refer to the risks and/or
benefits of using GM technology (in food). In the
studies that elicited WTP values when participants
received a particular type of information, posi-
tive information—associated with 14 estimates—
had the highest average WTP premium (48.8%).
Thereby, values for GM biofortified foods that
were associated with positive information about
GM technology (57.3% 11 estimates) were sur-
prisingly valued more highly than those associated
with nutrition information (30.5%, three esti-
mates). When negative information was given, how-
ever, consumers were on average willing to pay 7.0%
less than for regular foods (11 estimates). Objective
GM information alone, though only measured in
one study, averaged a premium of 24.5% (two esti-
mates). As far as conflicting GM information is con-
cerned, 22 estimates resulted in an average of 7.7%.
It is important to highlight the importance of the
order of providing conflicting GM information. If
positive information precedes negative statements
on GM technology (8.2%, 11 estimates), values are
substantially lower than in the reverse order (18.0%,
three estimates), especially if objective information
(3.0%, eight estimates) is added. While the only
study that directly compared the order of conflict-
ing GM information found a primacy effect,47 by 
which information presented first is less effective
than what is shown last, the metaresults lend sup-
port for the opposite, known as a recency effect. The
seven studies that did not assess the effect of differ-
ent types of information on WTP for bioengineered
biofortified crops registered the second-highest
WTP premium (44.7%, no information treatment,
13 estimates).
Figure 2 provides detailed insights into the role
of information on consumers’ WTP for GM bio-
fortified crops. Notwithstanding the fact that a
similar information treatment often generates dif-
ferent WTP values, whether the targeted product,
micronutrient, or country is different or not, the
metafindings generally confirm the size and direc-
tion of each of those information effects.
Cost-effectiveness and cost–benefits
of GM biofortified crops
Systematic review. Table 2 provides an overview 
of the key findings of cost-effectiveness and cost–
benefit analyses on GM biofortification, as well as
its underlying health impact figures, per biofortified
product and country. By targeting vitamin A defi-
ciency in the Philippines, Zimmerman and Qaim56
were the first to conduct an economic-evaluation
study on GM biofortification, assessing the cost–
benefits of golden rice in 2004.
Together, the selected studies generated a total
of 14 cost-effectiveness analyses, either expressed in
USD per DALY saved (10 values), incremental cost-
effectiveness ratio (ICER, two values), or in USD per
life saved (two values), and 16 cost–benefit analyses,
of which 10 refer to the IRR and six to BCRs. Each
analysis makes a distinction between a low, pes-
simistic and a high, optimistic impact scenario. The
difference is mainly attributable to calculations or
assumptions related to the efficacy (e.g., improved
micronutrient content after postharvest processing
and, in the case of vitamin A, bioavailability) and the
potential market coverage (e.g., based on consump-
tion levels and/or farmer adoption) of the targeted
micronutrient intervention.
Furthermore, all studies measured the health
impacts of GM biofortification, expressed in mil-
lion DALYs saved per year (14 values). Except for the
study of Chow et al.,57 each study also reported fig-
ures on the current burden of the targeted micronu-
trient deficiency (six values) and, per impact sce-
nario, the percent reduction in burden through
introducing GM biofortification (12 values).
From the conducted review, nearly all economic-
evaluation studies targeted GM-biofortified
rice,56,58–60 either enriched with folate58,59 or
vitamin A56,58,60 or as a multi-biofortified GM crop
with a high level of transgenic (vitamin A and
folate) and conventional traits (iron and zinc).58
Only one study57 examined the potential of another
product, namely golden mustard oil as a means to
tackle the vitamin A burden. All analyses originated
from Asia, particularly China,58,59 India,57,60 and
the Philippines.56 One of the Chinese studies62 was
particularly oriented toward Shanxi Province as a
target region, given the extremely high prevalence
of folate deficiency and neural-tube defects (NTDs)
as its main adverse health outcome.63 As none of
the GM biofortified foods are approved for com-
mercialization, these analyses have to be considered
as ex-ante evaluation studies, in which the potential
relative cost-effectiveness or cost–benefit is assessed
over a time horizon from 16 to 30 years.
Assessments of the current burden of the specific
micronutrient deficiencies in the study locations are
inherent to economic evaluations of health inter-
ventions. Depending on the targeted vitamin and
population, between 0.11 million (folate deficiency
in Shanxi Province) and 10.64 million DALYs (mul-
tiple micronutrient deficiencies in China) are lost
each year. Although such absolute figures are inter-
esting from a public health perspective, the impacts
of GM biofortification will be mainly discussed in
terms of relative numbers (e.g., percent reduction of
the burden or cost per DALY saved). In general, GM
biofortified crops, regardless of the micronutrient
they target, could lower the burden of micronutri-
ent deficiencies to a substantial extent, from 5.7% to
60.0%, in a very cost-effective way (USD 120.3–3.1
per DALY saved).
Rice (folate, vitamin A, multiple micronutrients).
Notwithstanding the relatively low burden of folate
deficiency, partially because the analysis only tar-
geted one of its functional outcomes (i.e., NTDs),
introducing GM rice with a higher folate content
into China58 or Shanxi Province59 leads to a 20–
60% reduction of the burden, respectively, 0.06–
0.19 and 0.02–0.07 million DALYs gained per year.
Given the larger absolute benefits, a countrywide
implementation leads to a higher cost-effectiveness
(i.e., USD 21.4–64.2 per DALY saved, as compared
to USD 40.1–120.3 per DALY saved in the regional
analysis). Depending on the impact scenario and
the study location, the implementation of golden
rice would reduce the burden of vitamin A defi-
ciency by 17–60% (China),58 8.8–59.4% (India),60
and 5.7–31.5% (the Philippines).56 In China and 
India, such an intervention would be considered
highly cost-effective, as the cost per DALY through
golden rice varies between USD 5.0 and 18.1 (or
USD 54–358 per life saved), and USD 3.1–19.4,
respectively. If vitamin A and folate were combined
with zinc and iron into multi-biofortified rice, it
would only cost USD 2.3–9.6 to save a DALY in
China and reduce the burden of four micronutri-
ent deficiencies at the same time (11–46%). When
gene stacking would be possible, by which the dif-
ferent traits are inserted in one gene construct
and transferred into a new stacked event, the cost-
effectiveness ratio would even be higher (USD 1.9–
7.9 for saving a DALY58). In any case, when com-
pared with the World Bank’s64 threshold for highly 
cost-effective interventions (i.e., USD 273 per DALY
saved in 2015), the estimated impacts of all GM
biofortified rice varieties verify the costs of their
introduction. With respect to cost–benefit analysis,
the IRR of golden rice in India and the Philippines
is substantially higher than the minimum required
return for health-related interventions60 (i.e., 10–
12%), regardless of the impact scenario or the cost
assigned to a DALY. In India, the (highly) positive
BCRs lend further support for golden rice to be
implemented.
Mustard oil (vitamin A). Chow et al.57 used 
ICERs to calculate the additional cost of mov-
ing from vitamin supplementation to vitamin
A–enriched mustard oil in India. Although the
incremental cost of the latter is relatively large (USD
405–450 per DALY saved), GM biofortification
would avert 0.9–1.7 million DALYs per year, which
is far more than supplementation or fortification.
The number of lives saved, as well as the IRR range
(22–43%), further demonstrates that the impacts
of golden mustard oil would be more or less similar
as those of golden rice in India.
Meta-analysis. Table 4 summarizes the metafind-
ings of three types of outcome indicators, namely
burden of disease (million DALYs lost per year),
health impacts (million DALYs saved per year,
percent reduction of the burden), and economic-
evaluation indicators (cost-effectiveness, in USD per
DALY saved; cost–benefit, in percent IRR). Thereby,
average values will be described for three study char-
acteristics: crop, micronutrient, and country. BCR
figures were only included in the golden rice study
of Stein et al.60 and, therefore, not discussed in the
meta-analysis.
Across all categories and studies, GM biofortifi-
cation could save each year, on average, between 0.5
and 1.6 million DALYs of all the targeted DALYs that
are lost owing to micronutrient deficiencies (i.e.,
15.6 million in total, or 3.1 million DALYs on aver-
age, based on the available absolute burden figures).
This translates to an average reduction of the burden
by 12.5% and 51.4%, depending on the impact sce-
nario. As far as economic impacts are concerned, to
save a DALY through GM biofortification, it would
cost on average USD 27.8 (low impact) and USD
7.9 (high impact). Based on the high average IRR
across studies, ranging from 39.2% to 82.4%, the
potential of GM biofortification and rice in partic-
ular becomes clear.
Crop. The metaresults indicate that the average
amount of DALYs saved through GM biofortified
rice is somewhat lower than for oil from GM bio-
fortified mustard, though the latter was only exam-
ined once. In terms of cost–benefits, however, IRRs
of introducing micronutrient-enriched GM rice are
more than twice as large as in the case of mustard
oil. The relatively large costs of the latter (i.e.,
about 36 times higher than the cost of the relatively
most expensive GM biofortified crop (e.g., multi-
biofortified rice in China, USD 85.4 million)58)
mainly account for this.
Micronutrient. Although the estimates for folate-
and multi-biofortified rice varieties were built upon 
a single study in China,58 it is no surprise that the 
most positive outcomes were reported for a health 
intervention that addresses multiple micronutrient 
deficiencies simultaneously. Comparison of single-
biofortified foods shows that golden rice and mus-
tard oil together are substantially more cost-effective 
(USD 18.8–4.1 per DALY gained) than folate-
biofortified rice (USD 64.0–21.4 per DALY gained). 
Even so, the latter is also considered to be highly 
cost-effective and reduces its targeted deficiency 
to a larger extent (20.0–60.0% as compared with 
10.5–50.3%), especially in the low-impact scenario. 
The differences between vitamin A and folate are 
mainly attributable to the effectiveness, as vita-
min A–enriched foods generally address a larger 
problem—at least, according to the number of func-
tional outcomes included in their calculations—
at a relatively similar cost (e.g., USD 31.6 million 
and USD 48.9 million for, respectively, golden and 
folate-biofortified rice in China).58
Country. Country-specific differences in micro-
nutrient deficiencies lead to substantial variation 
in burden of disease (0.11–10.64 million DALYS 
lost per year) and absolute reduction through GM 
biofortification (0.02–4.91 million DALYs saved per 
year), particularly between large (China, India) and 
smaller countries (Philippines) or regions (Shanxi 
Province). But relative outcome indicators, like 
the annual percent reduction in burden, cost-
effectiveness ratio, and IRR, also vary between coun-
tries and impact scenarios.
Case study on folate-biofortified rice
In this case study, we present findings from vari-
ous socioeconomic studies on the market potential 
of folate-biofortified rice. Following the aforemen-
tioned studies on WTP or cost-effectiveness, this 
section mainly elaborates on their determinants (at 
the individual level, rather than at the study level). 
All studies build upon a more generic framework to 
analyze the socioeconomic potential of GM crops 
with health benefits,36 allowing for more in-depth 
information on other indicators, such as consumer 
acceptance of negative product attributes. Studies 
have been conducted in China and Shanxi Province 
(North China) and the Balrampur District of Uttar 
Pradesh (Northwest India). Their relevance is illus-
trated by their prevalence rates of folate deficiency
and NTDs, which are among the world’s highest.65,66
Not surprisingly, the sample is often solely target-
ing women of childbearing age as one of the main
beneficiaries of folate interventions.
Folate, folate deficiency, and folate-biofortified
rice. Folate, which belongs to the group of water-
soluble B vitamins, can be obtained through the
diet,67 with green and/or leafy vegetables, eggs, liver,
and certain fruits as the most important dietary
folate sources.68 As an alternative option, one could
also opt for its synthetic form, known as folic acid,
either as a supplement or as a fortified, processed
food. Despite these different options to increase
folate intake levels, folate deficiency is still prevalent
in various parts of the world and remains a major
public health issue. Inadequate folate consumption
has been associated with cardiovascular and coro-
nary diseases, megaloblastic anemia, stroke, depres-
sive disorder, schizophrenia, Alzheimer’s disease,
and—despite inconclusiveness regarding the direc-
tion of the effect—cancer.67,69,70 Furthermore, peri-
conceptional folate deficiency increases the onset of
various pregnancy-related diseases and outcomes,71
with most evidence for NTDs.72,73
In 2007, rice was for the first time success-
fully biofortified with folate using transgenic breed-
ing techniques.17 Through the overexpression of
Arabidopsis transgenes in rice endosperm, folate
levels of 100-fold above wild type could be
obtained. Recently, folate concentrations were fur-
ther increased, up to 150 times the initial lev-
els, while folate stability was enhanced through
complexation with folate-binding proteins, making
long-term storage possible.18
Given the low folate concentrations in current rice
varieties, as in other staple crops, like potatoes,68 it
is no surprise that the top rice-consuming countries
(e.g., Cambodia, Bangladesh, Myanmar, Thailand,
and China) are leading the charts when it comes
to the prevalence of folate deficiency and NTDs.18
Therefore, Southeast Asia is generally considered the
key target area for implementing folate-biofortified
rice.
Determinants of willingness to pay for folate-
biofortified rice. Consumers’ WTP for folate-
biofortified rice in the Chinese Shanxi Province was
elicited through a hypothetical consumer survey in
2008,46 as well as non-hypothetical auctions with
women of childbearing age in 2011.47,51,52 Besides
the discrepancy in valuations between both meth-
ods, by which higher premiums were obtained in 
the former, known as hypothetical bias,55 these two 
studies revealed different insights in the potential 
market demand for this GM crop, regardless of 
their average WTP level (see also Table 1). First, the 
survey demonstrated a positive effect of objective 
GM food knowledge, acceptance of GM rice, and 
GM food-risk perceptions, whereas GM food price 
perceptions negatively affected WTP.46 When look-
ing at (subsistence) farmers, premiums increased 
when they had a low income or lived in rural areas, 
which underlines the appropriateness of bioforti-
fication in targeting poor, rural populations. As 
acceptance is considered a precursor of consumers’ 
willingness to purchase a premium, this study also 
examined this concept and the role of negative 
attribute changes. In general, about 62.2% of the 
Shanxi consumers accepted this crop in 2008. Aside 
from indifferent consumers (26.6%), only 11.2%
expressed their reluctance. When also taking into 
account consumers’ GM food knowledge, risk and 
benefit perceptions, and the acquisition of and their 
trustworthiness in GM information, segmentation 
analysis identified three distinct consumer profiles: 
enthusiasts (14.2%), cautious consumers (44.6%), 
and opponents (41.2%).74 Enthusiasts generally 
obtained a high score on all variables, hence the 
smaller size of this segment. However, as the 
cautious segment can be treated as less optimistic 
rather than reluctant, the profiling further confirms 
the positive reactions in this target region. However, 
this is under the condition that folate-biofortified 
rice does not alter conventional rice attributes. If 
key attributes, like taste or environmental impacts, 
would be negatively affected, the initial, potential 
coverage rate (62.2%) would be more than halved 
(−54%).75 Surprisingly, the impact of changes 
in external appearance (−26.1%) and cultivation 
potential (19.6%) were considered less important.
Second, the experimental auction study47 not 
only determined Shanxi consumers’ WTP for folate-
biofortified rice at different (GM) information lev-
els (see also Table 1 and Fig. 2), but also confirmed 
the positive effects of objective GM knowledge and 
GM food acceptance52 on consumers’ intention to 
purchase (82.5% of the sample prepared to pay a 
premium) and, in line with the aforementioned 
survey,46 their actual WTP values. Furthermore, a 
target-group effect was found, highlighting signifi-
cantly lower WTP values for female students as com-
pared with female adults, who broadly embraced
GM technology. An additional comparative analy-
sis of the information treatments51 demonstrated
that the average premium Shanxi women are pre-
pared to pay for GM folate-biofortified rice (33.9%)
is slightly but significantly lower than its conven-
tional biofortified counterpart (36.5%). Premiums
for both folate-biofortified rice types were rela-
tively high, even if consumers could also opt for
an alternative non-GE product based on folic acid
supplements. Together with the low share of con-
sumers who are opposed to buying biofortified
rice (e.g., 17.5% when GM technology is involved),
these results further underline the attractiveness of
(GM) biofortified rice with a higher folate content
in this high-risk region. In other words, regardless
of potential negative perceptions of GM technology,
the tangible health benefits associated with GM bio-
fortified crops are dominating consumers’ trade-off.
Determinants of cost-effectiveness of folate-
biofortified rice. By applying the DALY frame-
work to biofortification, its cost-effectiveness is
determined by input parameters and assumptions
that are associated with (1) the assessment of the cur-
rent burden of targeted micronutrient deficiency,
(2) the health benefits (reduced burden through
folate-biofortified rice), and (3) the costs that are
incurred for its development and implementation.
As these are dependent on the specific case, its
role will be discussed in view of two health-impact
studies on folate-biofortified rice (not included in
the meta-analysis) (i.e., one targeting all Chinese
regions63 and another comparing two high-risk
regions in Asia (Shanxi Province versus Balrampur
District))76 and the two cost-effectiveness analyses
on China58 and its Shanxi Province59 (see Table 2).
First, the application of the DALY formula to
calculate the burden of folate deficiency is limited
to different types of NTDs, as these are the only
functional outcomes for which there is robust evi-
dence on the attribution level and the prevalence
rate. Aside from other DALY parameters, such as the
discount rate for future costs and benefits (3%),37
both factors directly influence the total number of
DALYs that are currently lost and, thus, can be saved
through folate biofortification. For this reason, the
higher attribution level in Northern China (i.e.,
85% as compared with 40% in Southern China)
contributes to a relatively larger burden in the for-
mer region: 4.7 (north) versus 0.7 (south) DALYs 
lost per 10,000 persons per year63 (for an overview 
of the folate-deficiency burden per province, see 
supplementary materials of Ref. 63). Because the 
NTD prevalence rate is also taken into account, both 
Shanxi Province (China) and Balrampur District 
(India) lose most DALYs owing to folate deficiency76 
(respectively 14.3 and 22.8–39.9 DALYs lost per 
10,000 persons per year), which confirms their sta-
tus as the most affected regions.
Second, calculating the health impacts of 
folate-biofortified rice requires input regarding the 
characteristics of the biofortified crop and the cov-
erage rate of its introduction. Regarding the former, 
it is important to note that the added micronutrient 
content (1.4–2.9 g/g rice) largely depends on the 
postharvest folate losses (50–75%) and its bioavail-
ability (50%).58 Together with the current folate 
intake patterns and rice consumption levels, folate 
intake levels after biofortification could be com-
pared. In China, women of childbearing age could 
exceed the daily recommended nutrient intake level 
for folate when consuming folate-biofortified rice 
instead of a diet based on conventional rice.58 As 
such, a folate-biofortified diet may prevent women 
from delivering a baby with an NTD caused by folate 
deficiency,58 even in the NTD-prevalent regions 
of Northern China, where rice consumption levels 
are substantially lower than in the South.63 Despite 
the fact that not all women are assumed to switch 
to a biofortified rice diet, known as the coverage 
rate, about 20–60% of the Chinese burden of 
folate deficiency (i.e., of folate-related NTDs) could 
be eliminated through this crop.58,59 When using 
the aforementioned acceptance and WTP studies 
in Shanxi Province as an indicator of the potential 
coverage in high-risk regions, the health impacts 
would be even larger (i.e., 5.3–11.7 (Balrampur) 
and 8.4–32.7 DALYs gained (Shanxi)).76
Third, the high cost-effectiveness of folate-
biofortified rice is also a function of the costs asso-
ciated with its development and introduction. On a 
30-year time horizon, the total costs are estimated 
at about 32.4 million USD58 for China. There-
fore, pre- and postimplementation costs are more 
or less equally distributed. While the former cov-
ers research and development (8 years, 5.7 million 
USD) as well as costs for inserting the folate trait 
into the local rice varieties and efforts to deregu-
late it (6 years, 9.5 million USD), the latter refers
to social marketing (16 years, 15.0 million USD)
and maintenance breeding costs (16 years, 2.1 mil-
lion USD). Together with golden rice, which costs
slightly less in India (21.4–27.9 million USD)60 and
the Philippines (15.7 million USD)56 but more in
China (49.9 million USD),58 the examined GM bio-
fortified crops are also worth pursuing from an
economic perspective,19 even when targeting only
a high-risk region, like Shanxi Province.59
Conclusions
The process of applying transgenic breeding tech-
niques to introduce or enhance micronutrient con-
centrations in food crops has moved on apace in
the recent decade. With golden rice as the flagship,
researchers are increasingly providing evidence on
the market potential of GM-biofortified crops. The
turn of the century, when golden rice was assumed
to be ready for commercialization,24 can be seen
as the starting point of this field of socioeconomic
research. Since the golden rice experiment of Lusk
et al.40 in 2001, 11 economic-valuation studies have
elicited WTP for GM biofortified crops of con-
sumers from various backgrounds. Not much later,
research on the cost-effectiveness or cost–benefits
of the introduction of those crops took a leap, with
five studies targeting the Asian market. Through
systematic review and meta-analysis of these stud-
ies, this paper examined 64 and 30 estimates that
were obtained at the level of economic valuation
and evaluation, respectively.
The findings reveal positive consumer reactions
toward GM biofortified crops, with an average WTP
premium of 23.9%. Notwithstanding the contro-
versy around GM technology, its application to bio-
fortification did not lead to values that deviated from
those reported for conventional biofortified crops.26
While variations can be observed for type of crop,
micronutrient, and breeding technique, with higher
values for rice, vitamin A, and intragenic breed-
ing, nearly all premiums exceed the 10% level. Rice,
as one of the world’s most important staples, has
often been targeted for crop modification, which
is reflected in this socioeconomic review. There-
fore, the higher premiums for vitamin A–enriched
golden rice as compared with folate-biofortified rice
may point to the importance of vitamin A deficiency
and its earlier development77 and, thus, longer his-
tory of consumer awareness than folate-biofortified
rice.17 Further, transferring genes within the same 
family of crops (intragenic breeding) is more accept-
able to consumers than transgenic breeding, in line 
with recent findings on GM crops with improved 
agronomic traits in Europe.78
Unexpectedly, the type of country (developing 
versus developed) did not account for substan-
tial differences in consumer valuations. Although 
no European WTP studies were conducted, which 
correspond with the objective of biofortification 
in addressing malnutrition in developing regions, 
consumer reactions in the United States and New 
Zealand further confirmed the broad attractiveness 
of tangible consumer benefits in GM food.
Besides methodological differences, where we 
found support for the general discrepancy between 
values derived from hypothetical and non-
hypothetical study designs, it is the provision of 
information that also appears to be crucial. Pos-
itive information on GM technology (53.7%) or 
nutrition (31.5%) obtained the highest premium, 
followed by objective information (24.5%) and con-
flicting information, with higher values when neg-
ative information preceded positive information 
(18.0%) rather than vice versa (8.2%). This calls 
for further research on the role of information, 
what determines WTP at the consumer (rather than 
study) level (e.g., sociodemographics, knowledge, 
and attitude on GMOs), and how these crops should 
be delivered and marketed (e.g., labelling).
At the societal level, the health gains of GM bio-
fortified crops largely outweigh the costs associ-
ated with their development and commercializa-
tion. Across all simulations, between 12.5% and 
51.4% of the targeted burden of micronutrient defi-
ciency could be reduced at a relatively low cost (i.e., 
between USD 7.9 and USD 27.8 per DALY saved). 
Given the low micronutrient concentrations in cur-
rent staple crops, especially in rice,68 GM biofortifi-
cation has been shown to be a cost-effective means 
to tackle suboptimal micronutrient intake levels. 
Even under pessimistic assumptions, it should be 
considered an additional tool for alleviating the 
burden of hidden hunger, similar to conventional 
biofortification.8,25
The results also boost the evidence of vitamin A 
deficiency as a serious public health problem for 
which vitamin A biofortification can contribute to 
address its adverse health outcomes, including child 
mortality, but also may account for high valua-
tions of foods enriched with vitamin A. The lack
of evidence on the health contribution of delivering
adequate folate, besides its ability to reduce NTDs,
leads to a relatively lower burden of disease before
and after introducing folate biofortification. Despite
the (currently) limited scope, its application to rice
is highly (cost-)effective to target NTD prevalence
rates. The multi-biofortified approach for rice in
China is an excellent illustration of how economies
of scale can address the call for tackling various vita-
min and mineral deficiencies at a very low cost (i.e.,
below USD 10 per DALY averted).
Owing to the growing but limited research that
has been carried out with regard to the socioe-
conomics of GM biofortified foods, not all target
regions were represented in our analysis. Especially
when it comes to economic evaluation, all assess-
ments dealt with GM-biofortified rice in Asia. While
Asian rice-consuming countries, like India, are pri-
ority target markets, African socioeconomic stud-
ies are missing, urging for an extension of study
locations. Moreover, at the level of biofortification,
socioeconomic researchers often concentrate on few
micronutrients and crops and lag behind biotech
researchers, who have developed a wide array of bio-
fortified crops, beyond the troika of key micronutri-
ents (vitamin A, iron, zinc) and staples (wheat, rice,
corn).19 To anticipate and refine marketing strate-
gies, efforts are clearly needed to bridge the gap
between research and development and socioeco-
nomic evidence.
Through reviewing various socioeconomic stud-
ies on folate-biofortified rice and its determinants,
the case study further demonstrated the importance
of the epidemiological data on the effect of folate
deficiency and folate interventions when calculat-
ing its cost-effectiveness. Furthermore, the positive
figures were mainly a consequence of the efficacy
of the folate improvement in rice, the low recur-
rent costs, and the estimated coverage rate of its
implementation. Regarding the latter, folate-
enriched rice is generally accepted by its key ben-
eficiaries, such as women of childbearing age and
farmers from folate-deficient regions. To increase
acceptance and hence intervention coverage,
efforts should focus on information provision and
improvement of objective GM food knowledge.
From a developer’s point of view, it is important
to note that the promising acceptance rate (62.2%)
and WTP value (21.5–36.5%) assume that all
conventional rice attributes are unaffected. This 
may become an issue when inserting the folate trait 
in multi-biofortification as a highly cost-effective 
health strategy. The case study further highlights 
the need for combining micro-level analysis (e.g., 
acceptance, WTP studies) with macro-level simula-
tions (e.g., cost-effectiveness) when aiming to eval-
uate the socioeconomic potential of GM biofortified 
crops. To date, such an approach has only been used 
for golden and folate-biofortified rice.
While the combined focus on economic-
valuation and -evaluation studies is appropriate 
from a marketing and health policy perspective, 
many other research domains could contribute to 
evaluate and justify the potential of GM-biofortified 
crops. Research on stakeholder analysis,79,80 reg-
ulatory and policy issues (e.g., intellectual prop-
erty issues),81,82 and trade impacts83 is needed to 
identify and evaluate the most optimal way and 
platform to deliver biofortified foods. Moreover, 
building upon the challenges in terms of develop-
ment (e.g., micronutrient stability, bioavailability, 
field trials), efficacy, and effectiveness studies will 
be needed to feed socioeconomic analysis and fur-
ther underpin its importance.8,10 Nevertheless, the 
significant consumer acceptance and its promising 
cost-effectiveness in developing countries, particu-
larly in high-risk regions, show that—from a socioe-
conomic perspective—the time is right to launch 
and scale-up GM biofortification. In this perspec-
tive, the three reviews in this study provide food for 
thought for policy makers and health planners in 
priority target countries that seek a valuable, well-
accepted nutrition intervention that is grounded 
at the heart of the food supply chain and that is 
complementary to the existing strategies. As such, 
biofortification can optimize agriculture–nutrition 
linkeages84 and, especially when included in a holis-
tic and inclusive health strategy,7,85 contribute to 
brighten the future of nutrition.
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